These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

425 related articles for article (PubMed ID: 28038680)

  • 21. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Peripheral blood gene expression profiling shows predictive significance for response to mycophenolate in systemic sclerosis-related interstitial lung disease.
    Assassi S; Volkmann ER; Zheng WJ; Wang X; Wilhalme H; Lyons MA; Roth MD; Tashkin DP
    Ann Rheum Dis; 2022 Jun; 81(6):854-860. PubMed ID: 35190386
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cyclophosphamide for connective tissue disease-associated interstitial lung disease.
    Barnes H; Holland AE; Westall GP; Goh NS; Glaspole IN
    Cochrane Database Syst Rev; 2018 Jan; 1(1):CD010908. PubMed ID: 29297205
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mycophenolate versus cyclophosphamide for progressive interstitial lung disease associated with systemic sclerosis: a 2-year case control study.
    Panopoulos ST; Bournia VK; Trakada G; Giavri I; Kostopoulos C; Sfikakis PP
    Lung; 2013 Oct; 191(5):483-9. PubMed ID: 23925736
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Performance of Candidate Serum Biomarkers for Systemic Sclerosis-Associated Interstitial Lung Disease.
    Elhai M; Hoffmann-Vold AM; Avouac J; Pezet S; Cauvet A; Leblond A; Fretheim H; Garen T; Kuwana M; Molberg Ø; Allanore Y
    Arthritis Rheumatol; 2019 Jun; 71(6):972-982. PubMed ID: 30624031
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Two-year experience with mycophenolate mofetil in patients with scleroderma lung disease: a case series.
    Yilmaz N; Can M; Kocakaya D; Karakurt S; Yavuz S
    Int J Rheum Dis; 2014 Nov; 17(8):923-8. PubMed ID: 24864029
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Mycophenolate mofetil in systemic sclerosis-associated interstitial lung disease.
    Koutroumpas A; Ziogas A; Alexiou I; Barouta G; Sakkas LI
    Clin Rheumatol; 2010 Oct; 29(10):1167-8. PubMed ID: 20532938
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study.
    Štorkánová H; Oreská S; Špiritović M; Heřmánková B; Bubová K; Komarc M; Pavelka K; Vencovský J; Distler JHW; Šenolt L; Bečvář R; Tomčík M
    Sci Rep; 2021 Jan; 11(1):1. PubMed ID: 33414495
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Long-term follow-up of patients with scleroderma interstitial lung disease treated with intravenous cyclophosphamide pulse therapy: a single-center experience.
    Balbir-Gurman A; Yigla M; Guralnik L; Hardak E; Solomonov A; Rozin AP; Toledano K; Dagan A; Bishara R; Markovits D; Nahir MA; Braun-Moscovici Y
    Isr Med Assoc J; 2015 Mar; 17(3):150-6. PubMed ID: 25946765
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between immunosuppressive therapy and course of mild interstitial lung disease in systemic sclerosis.
    Hoa S; Bernatsky S; Steele RJ; Baron M; Hudson M;
    Rheumatology (Oxford); 2020 May; 59(5):1108-1117. PubMed ID: 31535689
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Expert consensus on the management of systemic sclerosis-associated interstitial lung disease.
    Rahaghi FF; Hsu VM; Kaner RJ; Mayes MD; Rosas IO; Saggar R; Steen VD; Strek ME; Bernstein EJ; Bhatt N; Castelino FV; Chung L; Domsic RT; Flaherty KR; Gupta N; Kahaleh B; Martinez FJ; Morrow LE; Moua T; Patel N; Shlobin OA; Southern BD; Volkmann ER; Khanna D
    Respir Res; 2023 Jan; 24(1):6. PubMed ID: 36624431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. KL-6 But Not CCL-18 Is a Predictor of Early Progression in Systemic Sclerosis-related Interstitial Lung Disease.
    Salazar GA; Kuwana M; Wu M; Estrada-Y-Martin RM; Ying J; Charles J; Mayes MD; Assassi S
    J Rheumatol; 2018 Aug; 45(8):1153-1158. PubMed ID: 29961690
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Plasma plasmin-α2-plasmin inhibitor complex levels may predict the effect of cyclophosphamide for systemic sclerosis-related interstitial lung disease.
    Saigusa R; Asano Y; Nakamura K; Yamashita T; Ichimura Y; Takahashi T; Toyama T; Taniguchi T; Yoshizaki A; Miyazaki M; Tamaki Z; Sato S
    Mod Rheumatol; 2017 Jul; 27(4):618-622. PubMed ID: 27538472
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Comparative efficacy and safety of immunosuppressive therapies for systemic sclerosis related interstitial lung disease: A Bayesian network analysis.
    Zheng JN; Yang QR; Zhu GQ; Pan L; Xia JX; Wang Q
    Mod Rheumatol; 2020 Jul; 30(4):687-695. PubMed ID: 31269839
    [No Abstract]   [Full Text] [Related]  

  • 35. Interstitial lung disease associated with systemic sclerosis: what is the evidence for efficacy of cyclophosphamide?
    Bérezné A; Valeyre D; Ranque B; Guillevin L; Mouthon L
    Ann N Y Acad Sci; 2007 Sep; 1110():271-84. PubMed ID: 17911442
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
    Maher TM; Corte TJ; Fischer A; Kreuter M; Lederer DJ; Molina-Molina M; Axmann J; Kirchgaessler KU; Samara K; Gilberg F; Cottin V
    Lancet Respir Med; 2020 Feb; 8(2):147-157. PubMed ID: 31578169
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Current concepts in disease-modifying therapy for systemic sclerosis-associated interstitial lung disease: lessons from clinical trials.
    Au K; Khanna D; Clements PJ; Furst DE; Tashkin DP
    Curr Rheumatol Rep; 2009 Apr; 11(2):111-9. PubMed ID: 19296883
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Use of mycophenolate mofetil for systemic sclerosis and systemic sclerosis-associated interstitial lung disease: Information from a Japanese hospital claims database.
    Funatogawa T; Narita Y; Tamura A; Mii K; Sugitani Y; Uchida T
    Mod Rheumatol; 2022 Jul; 32(4):755-760. PubMed ID: 34850080
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Effect of Bosentan on systemic sclerosis-associated interstitial lung disease ineligible for cyclophosphamide therapy: a prospective open-label study.
    Furuya Y; Kuwana M
    J Rheumatol; 2011 Oct; 38(10):2186-92. PubMed ID: 21885489
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma.
    Domiciano DS; Bonfá E; Borges CT; Kairalla RA; Capelozzi VL; Parra E; Christmann RB
    Clin Rheumatol; 2011 Feb; 30(2):223-9. PubMed ID: 20544245
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.